What did @cristina.noh actually say?
She's resuming a self-administered peptide protocol that includes GHK-Cu (skin and hair), "matzi" for metabolism, epithalon for longevity, "sameralan" for sleep, retatrutide and cagrilintide once weekly as a "substitution" for tirzepatide, and glutathione two to three times per week. She also wants to add BPC-157, which she calls the "glow peptide," expecting it to deliver "pretty much the same effects" as GHK-Cu. She pre-loads syringes four to five days ahead and recommends rubbing injection sites with what sounds like a castor oil roller to reduce post-injection bumps and bruising. The whole protocol is presented as a personal optimization routine with no mention of medical supervision, lab monitoring, or sourcing transparency.
Does the science back this up?
Some of it, partially, in specific contexts. GHK-Cu has legitimate published research behind it. Pickart and Margolina (2018, Biomolecules) documented its role in wound healing, collagen synthesis, and anti-inflammatory signaling. The skin-and-hair claim is the most defensible thing she says. Epithalon (epitalon) has animal and limited human data suggesting effects on telomerase activity and circadian rhythm regulation, with Khavinson's group publishing repeatedly in Bulletin of Experimental Biology and Medicine, though human RCT evidence remains thin. Glutathione as a systemic antioxidant and skin-brightening agent via IV or injection has some clinical backing, though oral bioavailability is poor and injectable protocols vary widely. Retatrutide and cagrilintide are investigational dual- and triple-receptor agonists still in Phase 2 and 3 trials. Calling them a replacement for tirzepatide is not supported by any published equivalency data.
What did they get wrong (or right)?
The retatrutide-plus-cagrilintide-as-tirzepatide-substitution claim is the most problematic. Tirzepatide (Mounjaro/Zepbound) is an FDA-approved GIP/GLP-1 dual agonist with extensive Phase 3 safety and efficacy data. Retatrutide adds GLP-1, GIP, and glucagon receptor activity; cagrilintide is an amylin analogue. These are not interchangeable compounds, and no published study supports using them together as a functional equivalent to tirzepatide. Pre-loading syringes for four to five days also raises legitimate sterility concerns. Most compounded peptides lack the preservatives found in commercial pharmaceutical vials, and the FDA and USP both flag multi-dose pre-loading as a contamination risk. On the positive side, her GHK-Cu skin rationale is reasonably grounded. And the castor oil tip, while anecdotal, is low-risk and not implausible given castor oil's documented anti-inflammatory properties (Vieira et al., 2010, Journal of Ethnopharmacology).
What should you actually know?
Self-directed injectable peptide stacks carry risks that go beyond whether individual compounds "work." Sterility, dosing accuracy, drug interactions, and the absence of baseline labs are real concerns. BPC-157, which she plans to add, has shown regenerative effects in rodent studies (Chang et al., 2011, Journal of Physiology and Pharmacology), but human RCT data is essentially nonexistent. The "glow peptide" label for BPC-157 is influencer shorthand with no clinical definition. Expecting it to replicate GHK-Cu's collagen-stimulating mechanism is a stretch: these compounds work through different pathways. None of the peptides in this stack are FDA-approved for the uses described. Some, like retatrutide and cagrilintide, are not approved for any use. Anyone watching this video and thinking about replicating this stack should understand that "I do this and it works for me" is not a safety profile.